AML Clinical Services

Executive Summary

AML Clinical Services is a Belgium-based contract research organization (CRO) founded in 2015 that provides specialized clinical research and consulting services exclusively for acute myeloid leukemia (AML). Unlike drug developers, the company supports biopharmaceutical firms and academic institutions in designing and executing clinical trials, leveraging deep expertise in this complex hematological malignancy. Operating as a pure service provider, AML Clinical Services benefits from the growing pipeline of AML therapies and the increasing outsourcing of specialized clinical functions by large pharma. The company's niche focus positions it as a strategic partner for sponsors seeking operational efficiency and regulatory navigation in AML. Despite limited public information, its established presence in a high-need therapeutic area suggests steady demand. Future growth is tied to the expansion of AML drug development and the company's ability to secure new contracts, though reliance on a single disease area introduces concentration risk.

Upcoming Catalysts (preview)

• Q3 2026New Partnership or Contract with Major Pharma60% success
• Q2 2026Presentation at Major Hematology Conference (e.g., EHA or ASH)80% success
• TBDExpansion of Service Offerings into Adjacent Indications (e.g., MDS)30% success